Novacyt Launches Yourgene Insight DPYD, a Genetic Test Prior to Chemotherapy
Novacyt announced on Tuesday the launch of the Yourgene Insight DPYD test, designed to identify cancer patients with a deficiency in dihydropyrimidine dehydrogenase (DPD) before chemotherapy treatment. The test, originally developed in 2019, has been enhanced to detect 19 genetic variants, including the 14 recommended by the updated guidelines of the Association for Molecular Pathology (AMP) and the American College of Medical Genetics and Genomics (ACMG).
Extended Variant Detection and Clinical Improvement
The test identifies patients with a DPD deficiency, an enzyme involved in the metabolism of 5-fluorouracil (5-FU), a chemotherapy drug commonly used in the treatment of colorectal, head and neck, breast, pancreatic, and stomach cancers. Between 10 and 20% of patients treated with fluoropyrimidines suffer from severe, sometimes fatal, side effects due to this deficiency. The Yourgene Insight DPYD test offers the same workflow and format as the original kit, with ready-to-use reagents, straightforward result interpretation, and a rapid turnaround time that allows for same-day results.
Regulatory Status and Market Context
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The product was launched for research use only (RUO), with regulatory approvals for in vitro diagnostic medical devices (IVDR) and other regulatory territories expected in due course. Many countries have already implemented DPYD genotyping before prescribing chemotherapy treatment, following a mixed model of private payment and reimbursement.
Related
SectorÉquipements et Services Médicaux›Équipements Médicaux
Context
Period
Period: 2025
Guidance from the release
La période de restructuration et d'intégration étant désormais clôturée, et l'activité stabilisée et moins risquée, nous nous sommes engagés à générer une croissance du chiffre d'affaires.
Croissance du chiffre d'affaires conforme aux attentes du marché; croissance semestrielle confirmée; pipeline solide pour 2026 et au-delà; groupe sans dette.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
